Navigate this market better. Subscribe for FREE stock alerts and information.

Thursday, February 6, 2014

BRIEF-AstraZeneca says internal drug development bigger focus than external deals, (NYSE: AZN)

AstraZeneca PLC CEO Pascal Soriot told reporters: * CEO says internal drug development a bigger focus in 2014 than external deal-making * CEO says needs large acquisition even less than a year ago *

AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. Shares of AZN traded higher by 0.83% or $0.52/share to $63.50. In the past year, the shares have traded as low as $44.46 and as high as $65.82. On average, 2178160 shares of AZN exchange hands on a given day and today's volume is recorded at 2237757.